Astellas Pharma Inc. (ALPMY)
OTCMKTS · Delayed Price · Currency is USD
15.74
+0.24 (1.55%)
At close: Feb 6, 2026

Astellas Pharma Balance Sheet

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Cash & Equivalents
254,296188,372335,687376,840315,986326,128
Cash & Short-Term Investments
254,296188,372335,687376,840315,986326,128
Cash Growth
41.38%-43.89%-10.92%19.26%-3.11%2.43%
Accounts Receivable
777,770632,525534,985427,965382,462343,178
Other Receivables
14,31713,69113,05117,81321,53913,984
Receivables
792,087646,216548,036445,778404,001357,162
Inventory
329,965297,261248,738174,386153,072164,080
Other Current Assets
64,92369,50062,26952,95050,29525,218
Total Current Assets
1,441,2711,201,3491,194,7301,049,954923,354872,588
Property, Plant & Equipment
352,402328,921293,742286,459269,044264,623
Long-Term Investments
191,333172,239163,018145,028141,206146,804
Goodwill
436,114415,207418,694328,411303,030284,011
Other Intangible Assets
1,052,0101,123,7141,453,824562,496623,431651,427
Long-Term Deferred Tax Assets
130,78198,11345,59484,16972,33154,176
Other Long-Term Assets
-111-1-1
Total Assets
3,603,9113,339,5443,569,6032,456,5182,332,3952,273,628
Accounts Payable
181,951187,840185,193140,236130,739124,777
Accrued Expenses
-169,119155,233143,817136,553124,898
Short-Term Debt
405,275184,874420,39375,00090,000120,000
Current Portion of Long-Term Debt
-81,65851,885-50,000-
Current Portion of Leases
-16,33514,94413,54617,73016,101
Current Income Taxes Payable
61,01734,54938,5155,13732,3888,395
Other Current Liabilities
676,344387,235419,562348,298230,001198,201
Total Current Liabilities
1,324,5871,061,6101,285,725726,034687,411592,372
Long-Term Debt
320,000564,893449,93754,21767680,400
Long-Term Leases
-89,32670,75661,46155,01462,163
Pension & Post-Retirement Benefits
23,23422,74624,67424,81837,22638,982
Long-Term Deferred Tax Liabilities
11,0485,35351,3466,0485,82318,161
Other Long-Term Liabilities
160,17582,36191,17775,98685,93795,435
Total Liabilities
1,839,0441,826,2891,973,615948,564872,087887,513
Common Stock
103,001103,001103,001103,001103,001103,001
Additional Paid-In Capital
184,578185,259184,070181,280179,467177,830
Retained Earnings
855,034740,939809,400908,158944,261953,289
Treasury Stock
-35,125-37,524-33,783-25,123-13,934-15,377
Comprehensive Income & Other
655,634521,580533,300340,638247,513167,372
Shareholders' Equity
1,764,8671,513,2551,595,9881,507,9541,460,3081,386,115
Total Liabilities & Equity
3,603,9113,339,5443,569,6032,456,5182,332,3952,273,628
Total Debt
725,275937,0861,007,915204,224213,420278,664
Net Cash (Debt)
-470,979-748,714-672,228172,616102,56647,464
Net Cash Growth
---68.30%116.09%-
Net Cash Per Share
-261.33-416.61-373.5394.5855.4225.54
Filing Date Shares Outstanding
1,7911,7901,7931,7971,8271,853
Total Common Shares Outstanding
1,7911,7901,7931,7971,8271,853
Working Capital
116,684139,739-90,995323,920235,943280,216
Book Value Per Share
984.26845.25890.07839.26799.26748.03
Tangible Book Value
274,998-25,666-276,530617,047533,847450,677
Tangible Book Value Per Share
153.52-14.34-154.22343.42292.19243.21
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.